Colesevelam Hydrochloride (Welchol)

11/01/2007 - "Improved tolerability of newer BAS (eg, colesevelam hydrochloride) and a "new" appreciation of the historic benefits of these "old" therapeutic agents may lead to an increased treatment role for these drugs, particularly in hypercholesterolemic patients with type 2 diabetes mellitus."
01/01/2010 - "This was a 52-week open-label extension study conducted at 63 sites in the United States and one site in Mexico to further evaluate the safety and tolerability of colesevelam hydrochloride in subjects with type 2 diabetes. "
02/01/2009 - "Literature search of colesevelam studies and abstracts assessing the benefits in managing type 2 diabetes mellitus. "
05/01/2020 - "This review discusses the potential for the use of colesevelam in the management of type 2 diabetes. "
05/01/2020 - "Colesevelam in the management of type 2 diabetes."

01/01/2010 - "A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia."
01/01/2010 - "To investigate the safety and efficacy of colesevelam in adults with primary hypercholesterolemia. "
12/01/2013 - "Patients were evaluated for the following eligibility criteria: a diagnosis of hypercholesterolemia, ≥18 years of age at index date, baseline laboratory values ≤3 months before the index date, ≥12 months of treatment and follow-up, and no prior orders for colesevelam ≤12 months before the index date. "
12/01/2013 - "To examine outcomes associated with colesevelam treatment among patients with hypercholesterolemia in real-world clinical practice. "
10/01/2013 - "Multivariate analysis of factors associated with persistent colesevelam treatment among patients with hypercholesterolemia."

06/01/2014 - "In primary hyperlipidemia and in T2DM, colesevelam appeared to be generally as safe, well tolerated, and efficacious in patients aged ≥65 years as in those aged <65 years."
07/01/2012 - "Participants who self-identified as Hispanic during enrollment were included in this exploratory analysis evaluating the efficacy of colesevelam in Hispanics with primary hyperlipidemia and prediabetes. "
10/01/2013 - "A total of 42,549 adults with hyperlipidemia and/or type 2 diabetes mellitus who newly started colesevelam between January 1, 2005, and September 30, 2011, and who had continuous enrollment in employer-sponsored commercial health insurance or Medicare supplemental benefit plans for at least 6 months before and 12 months after the date of colesevelam initiation. "
07/01/2012 - "From a total of 216 subjects with primary hyperlipidemia and prediabetes, 153 Hispanics were included in this post hoc analysis; 77 subjects were randomized to colesevelam and 76 subjects were randomized to placebo. "
07/01/2012 - "To evaluate the efficacy and safety of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetes. "

09/01/2009 - "However, results of this trial will help to define the extent to which colesevelam HCl can help improve cardiometabolic risk factors for complications of type 2 DM in the first-line environment, and will also indicate the extent to which early intervention with colesevelam HCl can help to correct metabolic abnormalities associated with prediabetes."
05/01/2010 - "This article briefly reviews current treatment guidelines for patients with prediabetes and T2DM and the potential role of colesevelam in the management of prediabetes and T2DM with oral antidiabetes agents."
07/01/2012 - "Participants who self-identified as Hispanic during enrollment were included in this exploratory analysis evaluating the efficacy of colesevelam in Hispanics with primary hyperlipidemia and prediabetes. "
07/01/2010 - "Further study is warranted to determine whether colesevelam slows or prevents progression of prediabetes to type 2 diabetes."
07/01/2012 - "From a total of 216 subjects with primary hyperlipidemia and prediabetes, 153 Hispanics were included in this post hoc analysis; 77 subjects were randomized to colesevelam and 76 subjects were randomized to placebo. "

10/15/2011 - "Effect of colesevelam hydrochloride on glycemia and insulin sensitivity in men with the metabolic syndrome."
04/01/2010 - "The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study."
09/08/2023 - "Lastly, colesevelam did not affect glucose excursions and insulin sensitivity in WT or KO mice. "
05/01/2012 - "Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and β-cell function."
01/01/2012 - "Colesevelam does not affect hepatic or peripheral insulin sensitivity and does not directly affect glucose absorption."